SAVANNAH is an ongoing, single-arm, phase II clinical study investigating the efficacy and safety of osimertinib (80 mg once daily) plus savolitinib (300 mg twice daily) in patients with EGFR-mutant NSCLC and acquired MET-mediated resistance to first-line therapy with osimertinib [77]. Here, MET is linked to non-small cell lung carcinoma.